Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.

Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.

The conversation discusses hair loss treatments, specifically topical finasteride and minoxidil, with users debating the effectiveness and honesty of progress pictures. Some users claim significant regrowth, while others argue about the influence of lighting and angles on perceived results.

A 24-year-old male was advised against an immediate hair transplant due to a weak donor area and was recommended to use PRP, oral minoxidil, and finasteride for a month before reassessment. Users suggested continuing finasteride and minoxidil for a longer period, as results typically take more than a month, and some expressed skepticism about the doctor's recommendations.

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

Bimatoprost was discussed for hair loss, with concerns about long-term scalp effects. A user reported no substantial effect after 6 months of use.

The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.

An 18-year-old is using finasteride for hair loss prevention despite having a healthy hairline. Opinions are mixed, with some advising against its use at his age and others supporting his proactive approach.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

The user is concerned about patchy hair regrowth after 5.5 months of treatment. They are questioning if more hair growth can be expected in the upcoming months.

A user plans to stop Dutasteride to conceive a child, seeking advice on hair maintenance. Suggestions include switching to Finasteride, but many emphasize prioritizing child safety.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

After nearly four months on finasteride, a user noticed improved hair quality but developed nipple puffiness, suggesting early signs of gynecomastia. They considered switching to other treatments like CB-03-01 or RU58841 and contemplated consulting an endocrinologist about aromatase inhibitors.

A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.

PP405 trials have completed phase 2a, showing promising results with a 31% stat for hair density increase, and are moving directly to phase 3. Detailed results will be presented at a medical conference in 2026.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

A user shared their experience with hair transplant success and stopping finasteride due to side effects like brain fog. They are content with potential hair loss and prioritize health over hair maintenance.

The user experienced significant hair regrowth using spironolactone, estradiol, minoxidil, and finasteride while transitioning. They noted reduced libido and increased grogginess as side effects.

The user reports some hair regrowth after four months of using finasteride and minoxidil chewables, noting baby hairs but no significant change in the hairline. Others encourage the user to continue the treatment, with some expressing regret for not starting earlier.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

A user is considering starting spironolactone for androgenetic alopecia but is concerned about stopping it before pregnancy. Another user suggests trying topical treatments as an alternative.

The user is considering using topical dutasteride to prevent hair loss progression from Norwood 1 to Norwood 2 at age 25, and is concerned about the long-term effectiveness and potential shedding from the treatment. They are currently using a shampoo with caffeine, rosemary, and saw palmetto, and have noticed hair thinning and changes since age 20.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

The user is applying topical finasteride with stemoxydine for hair loss and has noticed hair thickening but no regrowth after two months. They also report high SHBG and prolactin levels and a lack of morning erections, even on low doses of medication.

A 21-year-old male diagnosed with telogen effluvium and male pattern baldness started taking finasteride, which initially slowed hair shedding and slightly thickened hair. The doctor recommended iron and vitamin D supplements, and the user is considering minoxidil but wants to stabilize shedding first.

A user regrets not starting finasteride earlier for hair loss, noticing significant crown thinning by age 30. They have started using finasteride and are considering minoxidil for better hair regrowth.

A user shared an 8.5-month update on their hair transplant of 1064 grafts done by Dr. Kaan Pekiner in Ankara, Turkey, costing $3500. They are also using finasteride 2.25 mg weekly and have reduced shampoo use.

The user is generally happy with their hair transplant results but has concerns about graft density and placement, particularly on the left temple and hairline. They are using finasteride and minoxidil inconsistently, plan to add Priorin, and are considering microneedling and PRP sessions for future care.

Dutasteride and finasteride may affect sperm quality and fertility, with recommendations to stop use before trying to conceive. Dutasteride takes 4-6 months to clear from the system, while finasteride clears in about a week, but waiting longer is advised for optimal fertility.